On February 2, 2024, plaintiffs in nine lawsuits involving Ozempic and other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) petitioned to consolidate the cases. At that time, the litigation involved 18 cases in eleven different courts. The number of lawsuits has continued to increase (Currently, 37 are pending consolidation.). An order was issued consolidating the cases… read more